
|Articles|June 1, 2001
Studies confirm low-dose oral contraceptive treats acne effectively
Washington - The results of Phase III clinical trials demonstrate the safety and efficacy of a low-dose oral contraceptive containing ethinyl estradiol 20 mcg and levonorgestrel 100 mcg (Alesse) for the treatment of moderate acne, reported Diane M. Thiboutot, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















